Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

The combination of talimogene laherparepvec (T-VEC) and pembrolizumab previously demonstrated an acceptable safety profile and an encouraging complete response rate (CRR) in patients with advanced melanoma in a phase Ib study. We report the efficacy and safety from a phase III, randomized, double-bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Chesney, Jason A., Ribas, Antoni, Long, Georgina V., Kirkwood, John M., Dummer, Reinhard, Puzanov, Igor, Hoeller, Christoph, Gajewski, Thomas F., Gutzmer, Ralf, Rutkowski, Piotr, Demidov, Lev, Arenberger, Petr, Shin, Sang Joon, Ferrucci, Pier Francesco, Haydon, Andrew, Hyngstrom, John, van Thienen, Johannes V., Haferkamp, Sebastian, Guilera, Josep Malvehy, Rapoport, Bernardo Leon, VanderWalde, Ari, Diede, Scott J., Anderson, James R., Treichel, Sheryl, Chan, Edward L., Bhatta, Sumita, Gansert, Jennifer, Hodi, Frank Stephen, Gogas, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870217/
https://www.ncbi.nlm.nih.gov/pubmed/35998300
http://dx.doi.org/10.1200/JCO.22.00343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870217/
https://www.ncbi.nlm.nih.gov/pubmed/35998300
http://dx.doi.org/10.1200/JCO.22.00343

Ejemplares similares